3 Healthcare Stock Stories for Wednesday Investment Wellness

Vivus (NASDAQ:VVUS): Closing price $12.16

Vivus has announced that the FDA approved its amendment and modification to the Risk Evaluation and Mitigation Strategy for Qsymia (phentermine and topiramate extended-release) capsules CIV. The amendment was submitted in October 2012, and permits Qsymia to be dispensed through certified retail pharmacies, alongside the existing network of certified mail-order pharmacies.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

VVUS

Nymox Pharmaceutical Corporation (NASDAQ:NYMX): Closing price $4.73

Nymox Announced positive new study findings that showed its NX-1207 Phase 3 treatment for benign prostatic hyperplasia (BPH or prostatic enlargement) exhibited no detectable effect on key male structures that are involved in sexual function. This evaluation provided new data that offered further scientific support of the highly selective sparing of prostatic nerves after NX-1207 treatment. What is more, in excess of 1,000 patients in clinical trials who have received Nymox’s NX-1207 have experienced no clinical sexual problems linked to the drug.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

NYMX

Amgen (NASDAQ:AMGN): Closing price $109.44

The firm will pay $24.9 million to resolve allegations that it gave kickbacks to long-term care pharmacy providers to lure them into using its Aranesp anemia drug rather than rival medicines, according to the Justice Department on Tuesday.The Department claimed that the world’s biggest biotech firm violated the United States False Claims Act via kickbacks paid to Omnicare, Kindred Healthcare, and PharMerica Corp in return for transferring Medicare and Medicaid patients to Aranesp to treat their anemia.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AMGN

Investing Insights: Does Mylan Have Upside Potential?

More Articles About:   ,  

More from The Cheat Sheet